0.81
-0.0343(-4.06%)
Currency In USD
| Previous Close | 0.84 |
| Open | 0.84 |
| Day High | 0.84 |
| Day Low | 0.8 |
| 52-Week High | 2.22 |
| 52-Week Low | 0.54 |
| Volume | 178,258 |
| Average Volume | 227,979 |
| Market Cap | 8.64M |
| PE | -0.45 |
| EPS | -1.82 |
| Moving Average 50 Days | 0.89 |
| Moving Average 200 Days | 0.89 |
| Change | -0.03 |
If you invested $1000 in Biofrontera Inc. (BFRI) since IPO date, it would be worth $9.18 as of September 08, 2025 at a share price of $0.81. Whereas If you bought $1000 worth of Biofrontera Inc. (BFRI) shares 3 years ago, it would be worth $32.93 as of September 08, 2025 at a share price of $0.81.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Biofrontera Inc. Announces Last-Patient-Out in Phase 2b Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Moderate to Severe Acne Vulgaris
GlobeNewswire Inc.
Aug 25, 2025 12:25 PM GMT
Final patient visit marks key milestone for Biofrontera, with top-line results expected Q1 2026Company plans FDA discussion in Q3 2026 to advance Phase 3 program and potential label expansionMore than 50 million people affected by acne in US each yea
Biofrontera Inc. Appoints George Jones as Chief Commercial Officer
GlobeNewswire Inc.
Aug 11, 2025 8:25 PM GMT
Woburn, MA, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company focused on the development and commercialization of photodynamic therapy (PDT), today announced the appointment of George Jon
Biofrontera Inc. to Report Second Quarter FY 2025 Financial Results on August 13, 2025
GlobeNewswire Inc.
Aug 04, 2025 6:00 PM GMT
Woburn, MA, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc., (Nasdaq:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization of dermatological products, announces it will report financial results